Published in Int J Chron Obstruct Pulmon Dis on May 28, 2012
Breathlessness During Exercise: Experience and Memory | NCT03458182
Predictors of Hospital Length of Stay in Patients with Exacerbations of COPD: A Cohort Study. J Gen Intern Med (2014) 0.85
Symptom burden in community-dwelling older people with multimorbidity: a cross-sectional study. BMC Geriatr (2015) 0.84
Comparison of modified Borg scale and visual analog scale dyspnea scores in predicting re-intervention after drainage of malignant pleural effusion. Support Care Cancer (2013) 0.81
A review of the most common patient-reported outcomes in COPD--revisiting current knowledge and estimating future challenges. Int J Chron Obstruct Pulmon Dis (2015) 0.81
Continuous metabolic monitoring based on multi-analyte biomarkers to predict exhaustion. Sci Rep (2015) 0.75
Application of a new parameter in the 6-minute walk test for manifold analysis of exercise capacity in patients with COPD. Int J Chron Obstruct Pulmon Dis (2014) 0.75
Determinants of change in physical activity during moderate-to-severe COPD exacerbation. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Benefits Achieved for Patients Through Application of Height-Adjustable Examination Tables. J Patient Exp (2017) 0.75
ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med (2002) 31.79
Psychophysical bases of perceived exertion. Med Sci Sports Exerc (1982) 30.13
Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med (1970) 12.81
ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med (2003) 8.83
The St George's Respiratory Questionnaire. Respir Med (1991) 8.49
Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J (2008) 5.38
The perception of breathlessness in asthma. Am Rev Respir Dis (1982) 4.17
Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J (2002) 4.01
Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med (1999) 3.31
Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J (2004) 3.19
Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health (2007) 3.16
Exercise capacity and ventilatory, circulatory, and symptom limitation in patients with chronic airflow limitation. Am Rev Respir Dis (1992) 2.93
Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire. Chest (2007) 2.67
Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest (2005) 2.15
A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnoea during exercise. Clin Sci (Lond) (1989) 2.06
Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J (2004) 1.98
Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. Am J Respir Crit Care Med (1995) 1.98
Treatment of dyspnea in COPD. A controlled clinical trial of dyspnea management strategies. Chest (1995) 1.70
Validity of the numeric rating scale as a measure of dyspnea. Am J Crit Care (1998) 1.36
Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res (2010) 1.31
Usefulness of the modified 0-10 Borg scale in assessing the degree of dyspnea in patients with COPD and asthma. J Emerg Nurs (2000) 1.26
Validation of a vertical visual analogue scale as a measure of clinical dyspnea. Rehabil Nurs (1989) 1.21
Breathlessness and exercise in patients with cardiorespiratory disease. Am Rev Respir Dis (1986) 1.15
Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med (2010) 1.13
Reproducibility of Borg scale measurements of dyspnea during exercise in patients with COPD. Chest (1995) 1.09
Interval versus continuous training in patients with severe COPD: a randomized clinical trial. Eur Respir J (1999) 1.01
Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease. Proc Am Thorac Soc (2006) 0.98
The sensations of pulmonary dyspnea. Nurs Res (1986) 0.98
Evolution of dyspnea during exercise in chronic obstructive pulmonary disease: impact of critical volume constraints. Am J Respir Crit Care Med (2011) 0.91
Effects of inhaled anticholinergic drug on dyspnea and gas exchange during exercise in patients with chronic obstructive pulmonary disease. Chest (1993) 0.90
Verbal descriptors of dyspnea in patients with COPD at different intensity levels of dyspnea. Chest (2007) 0.89
Continuous measurement of breathlessness during exercise: validity, reliability, and responsiveness. J Appl Physiol (1985) (2001) 0.87
Impact of bronchodilator therapy on exercise tolerance in COPD. Int J Chron Obstruct Pulmon Dis (2010) 0.86
Clinical evaluation of exertional dyspnea. Clin Chest Med (1994) 0.86
Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD. Eur Respir J (2001) 0.78
Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest (2007) 5.01
An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med (2012) 3.62
Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol (2008) 3.41
Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med (2010) 2.56
Tests of the responsiveness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation. Chest (2012) 2.34
Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health (2005) 2.32
Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med (2014) 2.00
Epidemiology of chronic obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon Dis (2012) 1.87
Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest (2006) 1.75
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63
Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thorac Soc (2007) 1.56
Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies. Europace (2013) 1.53
Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study. Eur Psychiatry (2008) 1.49
Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest (2006) 1.30
Development and validation of a patient satisfaction and preference questionnaire for inhalation devices. Treat Respir Med (2005) 1.25
Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. Value Health (2010) 1.21
(18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med (2011) 1.15
Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ (2007) 1.13
Measuring the effects of COPD on the patient. Respir Med (2005) 1.13
Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing potentially curative resection. Ann Surg Oncol (2010) 1.04
Help-seeking behavior of women with self-reported distressing sexual problems. J Womens Health (Larchmt) (2009) 1.03
Correlates of sexually related personal distress in women with low sexual desire. J Sex Med (2009) 1.03
Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol (2003) 1.02
Health-related quality of life and other patient-reported outcomes in the European centralized drug regulatory process: a review of guidance documents and performed authorizations of medicinal products 1995 to 2003. Value Health (2005) 1.01
Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. Am Heart J (2009) 1.00
Inflammation in COPD: implications for management. Am J Med (2012) 1.00
Recent advances in dyspnea. Chest (2015) 0.99
Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER. J Affect Disord (2008) 0.98
Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease. Value Health (2008) 0.95
Comparison of continuous and discrete measurements of dyspnea during exercise in patients with COPD and normal subjects. Chest (2004) 0.94
Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med (2014) 0.92
Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. BMC Pulm Med (2014) 0.92
Ease of care with patient controlled analgesia systems: questionnaire development and validation. J Adv Nurs (2007) 0.90
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. Thromb Haemost (2012) 0.90
Factors influencing depression endpoints research (FINDER): study design and population characteristics. Eur Psychiatry (2007) 0.88
Trans-10,cis-12 conjugated linoleic acid suppresses the desaturation of linoleic and alpha-linolenic acids in HepG2 cells. J Nutr (2002) 0.86
Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respir Med (2011) 0.86
Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc (2015) 0.85
Assessing patient report of function: content validity of the Functional Performance Inventory-Short Form (FPI-SF) in patients with chronic obstructive pulmonary disease (COPD). Int J Chron Obstruct Pulmon Dis (2012) 0.84
Distressing sexual problems in United States women revisited: prevalence after accounting for depression. J Clin Psychiatry (2009) 0.84
Donor transmitted anaplastic carcinoma in a kidney-transplant recipient. Transpl Int (2005) 0.84
Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence. J Med Econ (2010) 0.82
Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection. AIDS (2006) 0.82
Capturing patients' perspectives of treatment in clinical trials/drug development. Contemp Clin Trials (2011) 0.82
Is the EQ-5D responsive to recovery from a moderate COPD exacerbation? Respir Med (2011) 0.82
Content validation of two SF-36 subscales for use in type 2 diabetes and non-dialysis chronic kidney disease-related anemia. Qual Life Res (2010) 0.82
Association of the VEGF 936C>T polymorphism with FDG uptake, clinical, histopathological, and metabolic response in patients with adenocarcinomas of the esophagogastric junction. Mol Imaging Biol (2011) 0.81
Neuromodulatory effect of endogenous opioids on the intensity and unpleasantness of breathlessness during resistive load breathing in COPD. COPD (2011) 0.81
Effect of fluticasone propionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD. Eur Respir J (2013) 0.81
Estimation of physiologic ability and surgical stress score does not predict immediate outcome after pancreatic surgery. Pancreas (2011) 0.80
Cultivation of RPMI 2650 cells as an in-vitro model for human transmucosal nasal drug absorption studies: optimization of selected culture conditions. J Pharm Pharmacol (2012) 0.79
An indole-binding site is a major determinant of the ligand specificity of the GABA type A receptor-associated protein GABARAP. Chembiochem (2008) 0.79
Adjusting for COPD severity in database research: developing and validating an algorithm. Int J Chron Obstruct Pulmon Dis (2011) 0.78
Advantages of endurance treadmill walking compared with cycling to assess bronchodilator therapy. Chest (2009) 0.78
Conjugated linoleic acids lower the release of eicosanoids and nitric oxide from human aortic endothelial cells. J Nutr (2003) 0.78
Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease. Results of a pilot study. Eur Arch Psychiatry Clin Neurosci (2003) 0.77
Perceptual and physiologic responses during treadmill and cycle exercise in patients with COPD. Chest (2008) 0.77
Characteristics of female outpatients with urinary incontinence participating in a 6-month observational study in 14 European countries. Maturitas (2005) 0.77
Prospective Use of Descriptors of Dyspnea to Diagnose Common Respiratory Diseases. Chest (2015) 0.77
Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial. Eur Respir J (2012) 0.77
Free and total carnitine concentrations in pig plasma after oral ingestion of various L-carnitine compounds. Int J Vitam Nutr Res (2005) 0.76
American Thoracic Society statement on research priorities in respiratory nursing. Am J Respir Crit Care Med (2006) 0.76
One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest (2014) 0.76
A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation. Pharmacoeconomics (2013) 0.76
More is better once again! J Cardiopulm Rehabil (2005) 0.75
Are you fluent in the language of dyspnea? Chest (2008) 0.75
Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review. Pharmacoeconomics (2010) 0.75
Author's reply: To PMID 25114521. Int J Chron Obstruct Pulmon Dis (2014) 0.75
Hit the dyspnea target! J Cardiopulm Rehabil (2003) 0.75
Response. Chest (2014) 0.75
Is physical activity anti-inflammatory on the airways? Thorax (2007) 0.75
It's about time--directing our attention toward modifying the course of COPD. Respir Med (2008) 0.75
Coexpression of Lactobacillus brevis ADH with GDH or G6PDH in Arxula adeninivorans for the synthesis of 1-(R)-phenylethanol. Appl Microbiol Biotechnol (2014) 0.75
The effects of cis-9, trans-11 and trans-10, cis-12 conjugated linoleic acids on delta4-desaturation in HepG2 cells. Int J Vitam Nutr Res (2004) 0.75